CD135

From WikiMD's WELLNESSPEDIA

(Redirected from FLT3)

CD135‏‎, also known as FLT3 (Fms-like tyrosine kinase 3), is a protein that in humans is encoded by the FLT3 gene. It is a member of the class III receptor tyrosine kinase (RTK) family, which includes c-Kit, PDGFR, and FLT1. CD135 plays a crucial role in the survival, proliferation, and differentiation of hematopoietic cells.

Structure[edit]

CD135 is a type III receptor tyrosine kinase, characterized by five immunoglobulin-like domains in the extracellular region. The intracellular region of CD135 contains a juxtamembrane domain, a tyrosine kinase domain, and a C-terminal tail.

Function[edit]

CD135 is expressed on the surface of many hematopoietic progenitor cells. The binding of FLT3 ligand (FLT3L) to CD135 triggers dimerization and autophosphorylation of the receptor, leading to the activation of multiple signal transduction pathways. These pathways include the RAS/MAPK pathway, the PI3K/AKT pathway, and the STAT pathway, which regulate cell survival, proliferation, and differentiation.

Clinical significance[edit]

Mutations in the FLT3 gene are associated with poor prognosis in acute myeloid leukemia (AML). These mutations often result in constitutive activation of the receptor, leading to uncontrolled cell proliferation. FLT3 inhibitors are currently being developed as targeted therapies for AML.

See also[edit]


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.